Biomarker: c-Myc

Histology type: endometrial carcinoma

Region: Zibo

Study type: surgery

Followed up time :

Subgroup 1 name : Endometrial cancer

Subgroup 1 number: 60

Subgroup 2 name: Endometrial inflammatory hyperplasia control group

Subgroup 2 number: 30

Conclusion: C-Myc is highly expressed in serum and tumor tissues of EC patients. Both are correlated with TNM stage, primary infiltration, and lymph node or distal metastasis, which provides a scientific basis for the development of new biomarkers for the diagnosis of endometrial carcinoma.

Sample type : serum

Sample method: ELISA

Statictics: cutoff<45;cutoff>45

Cohort age: 23;22

Funtion Uniprot: Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3' (PubMed:24940000, PubMed:25956029). Activates the transcription of growth-related genes (PubMed:24940000, PubMed:25956029). Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis (PubMed:24940000, PubMed:25956029). Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells (By similarity). Functions with TAF6L to activate target gene expression through RNA polymerase II pause release (By similarity). Positively regulates transcription of HNRNPA1, HNRNPA2 and PTBP1 which in turn regulate splicing of pyruvate kinase PKM by binding repressively to sequences flanking PKM exon 9, inhibiting exon 9 inclusion and resulting in exon 10 inclusion and production of the PKM M2 isoform (PubMed:20010808).

UniProt ID: P01106

UniProt Link: https://www.uniprot.org/uniprotkb/P01106/entry

Biological function from UniProt: #Transcription #Transcription regulation

Molecular function from UniProt:

Subcellular UniProt: #Nucleus

Alternative name from UniProt:

Miscellaneous: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the four Yamanaka factors. When combined, these factors are sufficient to reprogram differentiated cells to an embryonic-like state designated iPS (induced pluripotent stem) cells. iPS cells exhibit the morphology and growth properties of ES cells and express ES cell marker genes.

Recommended name: Myc proto-oncogene protein

Gene name from HGNC: MYC (bHLHe39, c-Myc, MYCC)

HPA class: Cancer-related genes Disease related genes Human disease related genes Transcription factors

AlphaFold DB: P01106

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P01106

HPA link: https://www.proteinatlas.org/ENSG00000136997-MYC

Tissue specificity RNA from HPA: Tissue enhanced (adipose tissue, skin)

Tissue expression from HPA: Ubiquitous nuclear and nucleolar expression in essentially all cells except in glial- and stroma cells.

Single cell type specificity Cell type enhanced (Basal squamous epithelial cells, Basal prostatic cells, Suprabasal keratinocytes, Basal keratinocytes, Squamous epithelial cells)

Immune cell specificity: Low immune cell specificity

Subcellular summary HPA Located in Nucleoplasm

Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable), urothelial cancer (unfavorable) and ovarian cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000136997-MYC/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000136997-MYC/pathology/endometrial+cancer

Expression figure legend: C-Myc expression in patient tissues (×400).

Expression figure link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069412/figure/f2-medscimonit-24-4738/

Phenotype ID: 113970;

Disease: No disease ID;Burkitt lymphoma (BL);

Note1: The gene represented in this entry is involved in disease pathogenesis. Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.

OMIM: 190080;113970;

OMIM link1: https://www.omim.org/entry/113970

OMIM link2: https://www.omim.org/entry/190080;https://www.omim.org/entry/113970;

HGNC ID: HGNC:7553

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7553